WO2012087182A3 - Замещенные метил-амины, антагонисты серотониновых 5-нт6 рецепторов, способы получения и применения - Google Patents

Замещенные метил-амины, антагонисты серотониновых 5-нт6 рецепторов, способы получения и применения Download PDF

Info

Publication number
WO2012087182A3
WO2012087182A3 PCT/RU2011/000981 RU2011000981W WO2012087182A3 WO 2012087182 A3 WO2012087182 A3 WO 2012087182A3 RU 2011000981 W RU2011000981 W RU 2011000981W WO 2012087182 A3 WO2012087182 A3 WO 2012087182A3
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
fluorine
chlorine
hydrogen
methylpiperazin
Prior art date
Application number
PCT/RU2011/000981
Other languages
English (en)
French (fr)
Other versions
WO2012087182A2 (ru
Inventor
Александр Васильевич ИВАЩЕНКО
Олег Дмитриевич МИТЬКИН
Мадина Георгиевна КАДИЕВА
Original Assignee
Алла Хем, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алла Хем, Ллс filed Critical Алла Хем, Ллс
Priority to JP2013546064A priority Critical patent/JP6033788B2/ja
Priority to EP11851231.8A priority patent/EP2657225A4/en
Priority to US13/993,131 priority patent/US8829002B2/en
Priority to AU2011345414A priority patent/AU2011345414B2/en
Priority to CA2845524A priority patent/CA2845524A1/en
Priority to KR1020137018965A priority patent/KR20140023269A/ko
Priority to EA201300663A priority patent/EA201300663A1/ru
Publication of WO2012087182A2 publication Critical patent/WO2012087182A2/ru
Publication of WO2012087182A3 publication Critical patent/WO2012087182A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Настоящее изобретение относится к новым замещенным метил-аминам, антагонистам серотониновых 5-НТ6 рецепторов, к активным компонентам, фармацевтическим композициям, способу предупреждения и лечения заболеваний ЦНС и молекулярным инструментам, где новые замещенные метил-амины представляют собой соединения общей формулы 1 и их кристаллические формы, поликристаллические формы, фармацевтически приемлемые соли и/или гидраты, (1) где: W представляет собой нафталин, индолизин или хинолин; R1 представляет собой водород, фтор, хлор, метил; R2 представляет собой водород, фтор, метил, фенил, тиофен-2-ил, фуран-2-ил, пиридил, пиперазин-1-ил или 4-метилпиперазин-1-ил; R3 представляет собой метил; или W представляет собой бензол, R3 имеет вышеуказанное значение; R1 представляет собой 3-С 1, R2 представляет собой З-пиперазин-1-ил или 3-(4- метилпиперазин-1 -ил); или R1 представляет собой водород, R2 представляет собой фенил или пиридил; или R1 представляет собой водород, фтор, хлор, метил; R2 представляет собой 4-пиперазин-1 -ил или 4-(4-метилпиперазин-1 -ил); или W представляет собой оксазол, R3 представляет собой необязательно замещенный метил; R1 представляет собой хлор или фтор, R2 представляет собой метил, или R1 представляет собой водород, фтор, хлор, метил; R2 представляет собой пиперазин-1-ил, 4-метилпиперазин-1-ил, или R1 представляет собой хлор, фтор или метил; R2 представляет собой фуран-2-ил, или R1 представляет собой водород, фтор, хлор, метил; R2 представляет собой фуран-2-ил, R3 представляет собой (тетрагидрофуран-2-ил)метил, или R1 представляет собой водород, фтор, хлор, метил; R2 представляет собой тиофен-2-ил, R3 представляет собой 2- метоксиэтил, или R1 представляет собой хлор или фтор, R2 представляет собой тиофен-2-ил, R3 представляет собой метил.
PCT/RU2011/000981 2010-12-21 2011-12-13 Замещенные метил-амины, антагонисты серотониновых 5-нт6 рецепторов, способы получения и применения WO2012087182A2 (ru)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2013546064A JP6033788B2 (ja) 2010-12-21 2011-12-13 置換されたメチルアミン、セロトニン５−ｈｔ６受容体アンタゴニスト、製造のための方法及びその使用
EP11851231.8A EP2657225A4 (en) 2010-12-21 2011-12-13 SUBSTITUTED METHYL AMINES, 5-HT6 SEROTONIN RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING
US13/993,131 US8829002B2 (en) 2010-12-21 2011-12-13 Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for production and use thereof
AU2011345414A AU2011345414B2 (en) 2010-12-21 2011-12-13 Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for the production and use thereof
CA2845524A CA2845524A1 (en) 2010-12-21 2011-12-13 Substituted methyl amines, serotonin 5-ht6 receptor antagonists, methods for the production and use thereof
KR1020137018965A KR20140023269A (ko) 2010-12-21 2011-12-13 치환된 메틸아민, 세로토닌 5-ht6 수용체의 길항제, 이의 제조방법 및 이의 용도
EA201300663A EA201300663A1 (ru) 2010-12-21 2011-12-13 Замещенные метил-амины, антагонисты серотониновых 5-htрецепторов, способы получения и применения

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010152052 2010-12-21
RU2010152052/04A RU2443697C1 (ru) 2010-12-21 2010-12-21 Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения

Publications (2)

Publication Number Publication Date
WO2012087182A2 WO2012087182A2 (ru) 2012-06-28
WO2012087182A3 true WO2012087182A3 (ru) 2012-09-13

Family

ID=45852279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2011/000981 WO2012087182A2 (ru) 2010-12-21 2011-12-13 Замещенные метил-амины, антагонисты серотониновых 5-нт6 рецепторов, способы получения и применения

Country Status (9)

Country Link
US (1) US8829002B2 (ru)
EP (2) EP3072882A1 (ru)
JP (1) JP6033788B2 (ru)
KR (1) KR20140023269A (ru)
AU (1) AU2011345414B2 (ru)
CA (1) CA2845524A1 (ru)
EA (1) EA201300663A1 (ru)
RU (1) RU2443697C1 (ru)
WO (1) WO2012087182A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2500672C1 (ru) * 2012-10-25 2013-12-10 Андрей Александрович Иващенко (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
CN109134354B (zh) * 2018-09-19 2022-03-25 天津科技大学 2-吡啶甲基硫醚的合成方法及相关药物的合成工艺
EP4045485A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038316A2 (de) * 1999-11-25 2001-05-31 Merck Patent Gmbh Sulfonyloxazolamine und deren verwendung als 5-ht6 rezeptorliganden
WO2001098279A2 (en) * 2000-06-20 2001-12-27 Pharmacia & Upjohn Company Bis-arylsulfones
US20020115660A1 (en) * 2000-06-20 2002-08-22 Eric Jon Jacobsen Bis -arylsulfones
WO2002100842A1 (en) * 2001-06-13 2002-12-19 Merck Patent Gmbh Sulfonyloxazolamines and their use as 5-ht6 ligands
US20040014966A1 (en) * 2000-06-20 2004-01-22 Jacobsen Eric Jon Bis-arylsulfones

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538833B2 (fr) 1982-04-27 1986-04-25 Roux Paul Local enterre, tel que notamment une cave, procede d'amenagement de celui-ci et dispositif amovible de blindage utilise pour la mise en oeuvre dudit procede
SI0930302T1 (en) 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
DE19858593A1 (de) 1998-12-18 2000-06-21 Merck Patent Gmbh Sulfonyloxazolamine als therapeutische Wirkstoffe
EP1465872A1 (en) 2001-12-28 2004-10-13 Bayer Pharmaceuticals Corporation 4-sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
ES2307919T3 (es) * 2002-03-27 2008-12-01 Glaxo Group Limited Derivados de quinolina y su uso como ligandos de 5-ht6.
GB0419192D0 (en) * 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5575663B2 (ja) * 2008-01-24 2014-08-20 アンドレイ・アレクサンドロビッチ・イワシェンコ 置換された２−アミノ−３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用
RU2393157C1 (ru) * 2008-10-06 2010-06-27 Андрей Александрович Иващенко 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038316A2 (de) * 1999-11-25 2001-05-31 Merck Patent Gmbh Sulfonyloxazolamine und deren verwendung als 5-ht6 rezeptorliganden
WO2001098279A2 (en) * 2000-06-20 2001-12-27 Pharmacia & Upjohn Company Bis-arylsulfones
US20020115660A1 (en) * 2000-06-20 2002-08-22 Eric Jon Jacobsen Bis -arylsulfones
US20040014966A1 (en) * 2000-06-20 2004-01-22 Jacobsen Eric Jon Bis-arylsulfones
WO2002100842A1 (en) * 2001-06-13 2002-12-19 Merck Patent Gmbh Sulfonyloxazolamines and their use as 5-ht6 ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2657225A4 *

Also Published As

Publication number Publication date
US20130267536A1 (en) 2013-10-10
EP2657225A2 (en) 2013-10-30
JP6033788B2 (ja) 2016-11-30
JP2014508729A (ja) 2014-04-10
EA201300663A1 (ru) 2013-10-30
EP3072882A1 (en) 2016-09-28
US8829002B2 (en) 2014-09-09
CA2845524A1 (en) 2012-06-28
AU2011345414B2 (en) 2016-12-01
KR20140023269A (ko) 2014-02-26
RU2443697C1 (ru) 2012-02-27
EP2657225A4 (en) 2014-07-30
WO2012087182A2 (ru) 2012-06-28

Similar Documents

Publication Publication Date Title
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
EA200901253A1 (ru) ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
PE20151428A1 (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrogeno
JP2005513016A5 (ru)
TNSN07016A1 (en) Indole-2-carboxamidine derivatives as nmda receptor antagonists
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
WO2002012189A1 (fr) Composes amide bicycliques condenses et utilisations medicales associees
NO20083500L (no) 1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
JP2013539789A5 (ru)
GEP20125522B (en) Novel piperazine salts as d3/d2 antagonists
WO2009093209A3 (ru) 2-AЛKИЛAMИHO-3-APИЛCУЛЬФOHИЛ-ЦИKЛOAЛKAHO [e ИЛИ d] ПИPAЗOЛO [1,5-a] ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
MX2007005189A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarinico m3.
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
EA200701583A1 (ru) Гетероциклические тетрациклические производные гидрофурана в качестве ингибиторов 5нт2 в терапии расстройств цнс
WO2009013212A3 (en) Dual modulators of 5-ht2a and d3 receptors
NO20063602L (no) Benzyl(iden)-laktam-derivater
WO2012087182A3 (ru) Замещенные метил-амины, антагонисты серотониновых 5-нт6 рецепторов, способы получения и применения
TNSN07014A1 (en) New heterocyclic carboxylic acid amide derivatives
DK2197841T3 (da) Guanidinholdige forbindelser anvendelige som muscariniske receptorantagonister
NZ599132A (en) Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
JP2016512541A5 (ru)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11851231

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 13993131

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2013546064

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201300663

Country of ref document: EA

REEP Request for entry into the european phase

Ref document number: 2011851231

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011851231

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137018965

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201309132

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2011345414

Country of ref document: AU

Date of ref document: 20111213

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2845524

Country of ref document: CA